Product image of Klisyri (Tirbanibulin) supplied by GNH India

Klisyri

Active Ingredient:
Tirbanibulin
Origin:
EU

Klisyri (Tirbanibulin)

Tirbanibulin, the active ingredient in Klisyri, is a Src kinase inhibitor presented as a 1% w/w topical solution for topical use. It is indicated for the treatment of actinic keratosis on the face and scalp in adult patients, providing a localized therapeutic option.

GNH India supplies Klisyri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance across global markets, and providing reliable logistics for timely delivery to meet local health authority requirements.

Manufacturer / TM Owner

Almirall, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Klisyri (tirbanibulin) is a topical Src kinase inhibitor employed in dermatologic practice for the management of premalignant skin lesions caused by chronic sun exposure.

  • Actinic keratosis of the face: reduces precancerous lesions on facial skin.
  • Actinic keratosis of the scalp: clears lesions on the scalp area.
  • Field‑directed therapy for actinic keratosis: treats multiple lesions within a treated area, improving overall lesion burden.

How It Works

  • Tirbanibulin inhibits Src tyrosine kinase activity and interferes with tubulin polymerization in abnormal keratinocytes. This dual action leads to cell‑cycle arrest at the G2‑M phase and triggers apoptosis of dysplastic cells, resulting in the removal of actinic keratosis lesions while sparing surrounding healthy tissue.

Side Effects

Klisyri may cause local skin reactions, most of which are mild to moderate and resolve after treatment.

Common Side Effects

  • Erythema: redness at the application site.
  • Crusting: formation of a dry scab over treated lesions.
  • Pruritus: itching of the treated area.
  • Pain or tenderness: discomfort during or after application.
  • Swelling: mild edema around the lesion.
  • Dryness or flaking of skin.

Serious or Rare Side Effects

  • Severe allergic reaction: hives, swelling, or difficulty breathing.
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Bullous dermatitis: blister formation.
  • Secondary skin infection at the site.
  • Persistent ulceration or necrosis.
  • Uncontrolled pain requiring medical attention.

Precautions & Warnings

Before using Klisyri, consider the following safety measures.

  • Pregnancy: safety not established; avoid use unless clearly needed.
  • Breastfeeding: unknown risk; weigh benefits against potential exposure.
  • Application site: apply only to intact skin; avoid eyes, mucous membranes, and open wounds.
  • Surface area: do not exceed the prescribed treatment area or duration.
  • Monitoring: discontinue and seek medical advice if severe local reactions develop.
  • Store at room temperature: keep in the original container, protect from light and moisture.

Avoid Interactions

Klisyri has limited systemic absorption, but certain topical or systemic agents may influence its safety or efficacy.

Major Interactions (Avoid)

  • Concurrent use of other topical chemotherapeutic agents on the same area: may increase irritation.
  • Systemic immunosuppressants: could impair wound healing.

Moderate Interactions (Monitor Closely)

  • Topical corticosteroids applied to the same site: may reduce tirbanibulin efficacy.
  • Phototherapy or intense UV exposure: may heighten skin sensitivity.
  • Co‑application with other keratolytic agents: may enhance local irritation.

Frequently Asked Questions

Klisyri is a prescription topical solution containing tirbanibulin that is used to treat actinic keratosis, a precancerous skin condition, on the face and scalp of adult patients. It works by targeting abnormal skin cells to clear lesions.

Tirbanibulin blocks Src tyrosine kinase activity and interferes with tubulin polymerisation in abnormal keratinocytes. This stops cell division and induces programmed cell death, leading to the removal of actinic keratosis lesions while sparing normal skin.

The prescribed dose of Klisyri is determined by the treating physician based on the extent and location of the lesions. The medication is applied as a thin layer to the affected area for a defined period, typically once daily for a short course.

Safety of tirbanibulin in pregnancy and lactation has not been established. It is recommended to avoid use during pregnancy unless clearly necessary, and to consider potential risks versus benefits while breastfeeding.

To request Klisyri, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Klisyri offers a non‑invasive, short‑course topical option that directly targets abnormal keratinocytes via Src kinase inhibition. Compared with cryotherapy or 5‑fluorouracil, it provides a convenient field‑directed approach with a distinct mechanism and a generally well‑tolerated safety profile.

Klisyri should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from light and moisture, and keep it out of reach of children.

Klisyri is applied topically to the affected skin area. The prescriber will instruct the patient to spread a thin layer over each lesion, usually once daily for a limited number of days, and to avoid contact with eyes, mucous membranes and broken skin.

Serious risks, though rare, include severe allergic reactions, Stevens‑Johnson syndrome, bullous dermatitis, secondary skin infection, and persistent ulceration. Patients should seek immediate medical attention if they experience extensive blistering, swelling, difficulty breathing, or worsening pain.

Klisyri should not be used by individuals with known hypersensitivity to tirbanibulin or any excipients, on broken or infected skin, or in patients where safety during pregnancy or breastfeeding cannot be assured. It is also contraindicated on mucous membranes and ocular surfaces.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tirbanibulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT